Resolving the AUD Phenotype: Unique and Transdiagnostic Features and Genetic Heterogeneity

K.220.7：项目摘要/摘要 培训：拟议的K99/R00独立之路奖的主要目标是阿什利·瓦茨博士 她接受了酒精研究方面的培训，并开始了独立科学家的职业生涯。作为博士后 瓦茨博士是密苏里大学心理科学系的研究员， 成为一名领先的精神病理学研究者的道路。瓦茨博士寻求培训和指导 K99阶段，将重点缩小到酒精使用和酒精使用障碍，并获得更多的量化培训 遗传学和建模。澳元病因学方面的培训将侧重于澳元病因学；现代成瘾模式，包括 它们的关键神经行为机制；以及饮酒的个体差异。她将出席 与酒精使用/滥用、行为遗传学和精神病理学有关的会议。她还将出席 从人类到动物模型的行为和分子遗传学研讨会，以及神经科学 讲习班；每个讲习班都提供数量遗传技术的实践培训。这次培训 将极大地扩展瓦茨博士的基础知识和技能。瓦茨博士将把她的大量心血 通过编写手稿传播拟议研究结果的时间和 呈件。建议的导师和共同导师(Kenneth Sher博士和Andrew Heath博士)、合作者(Dr. Wendy Slutske、Douglas Steinley和Phillip Wood)以及顾问(John Crabbe博士、Arpana Agrawal博士、 凯瑟琳·布科尔茨、克里斯蒂娜·杰克逊和大卫·沃森)共同提供的专业知识非常适合 协助圆满完成拟议的培训和研究活动。此外，这所大学 密苏里州大学是一家世界级的研究机构，拥有推动成功完成研究的必要资源 拟议项目的培训(K99)阶段。 K99阶段：在监督下，瓦茨博士将对表型和基因进行二次数据分析 澳元内部的异质性。这项工作将使用大规模横截面和 纵向表型和遗传信息数据。她将通过导师、课程作业、 工作坊、读物和咨询。 R00阶段：Watts博士将确定AUD的特征是特定于酒精使用的，而不是一般的 物质使用，外化精神病理学，或更广泛地使用表型行为的精神病理学 遗传学和分子遗传学分析。 意义：她的工作最终将针对澳元内部的异质性来源，表征特定的澳元 脆弱性，并为未来的精准医学努力提供信息，NIAAA强调了每一项 重视提高AUD诊断水平，认识AUD与其他形式AUD的关系 精神病理学(NIAAA，2017)。

K.220.7: PROJECT SUMMARY/ABSTRACT Training: The major objectives of the proposed K99/R00 Pathway to Independence Award are Dr. Ashley Watts’ training in alcohol research and the launching of her career as an independent scientist. As a postdoctoral research fellow in the Department of Psychological Sciences at the University of Missouri, Dr. Watts is well along the path to becoming a leading psychopathology researcher. Dr. Watts seeks training and mentoring during the K99 phase to narrow her focus to alcohol use and alcohol use disorder and gain more training in quantitative genetics and modeling. Training in AUD will emphasize on AUD nosology; modern models of addiction, including their key neurobehavioral mechanisms; and individual differences in alcohol consumption. She will attend conferences related to alcohol use/misuse, behavior genetics, and psychopathology. She will also attend behavioral and molecular genetics workshops that span from human to animal models, as well as a neuroscience workshop; each of these workshops provides hands-on training in quantitative genetic techniques. This training will greatly extend Dr. Watts’ foundational knowledge and skill set. Dr. Watts will dedicate a great deal of her time to the dissemination of findings from the proposed research through manuscript preparation and submission. The proposed mentor and co-mentor (Drs. Kenneth Sher and Andrew Heath), collaborators (Drs. Wendy Slutske, Douglas Steinley, and Phillip Wood), and consultants (Drs. John Crabbe, Arpana Agrawal, Kathleen Bucholz, Kristina Jackson, and David Watson) collectively provide expertise that is ideally suited to facilitate the successful completion of the proposed training and research activities. Furthermore, the University of Missouri is a world-class research institution with the resources necessary to facilitate successful completion of the training (K99) phase of the proposed project. K99 Phase: With supervision, Dr. Watts will conduct secondary data analysis on phenotypic and genetic heterogeneity within AUD. This work will be achieved using a combination of large-scale cross-sectional and longitudinal phenotypic and genetically informative data. She will receive training via mentorship, coursework, workshops, readings, and consultation. R00 Phase: Dr. Watts will ascertain features of AUD that are specific to alcohol use, rather than general to substance use, externalizing psychopathology, or psychopathology more broadly using phenotypic, behavior genetic, and molecular genetic analysis. Significance: Her work will ultimately target sources of heterogeneity within AUD, characterize specific AUD vulnerabilities, and inform future precision-medicine efforts, each of which are emphasized by NIAAA’s emphases on the improvement of AUD diagnosis and understanding its relations with other forms of psychopathology (NIAAA, 2017).